Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCVAC/PCa plus docetaxel vs placebo plus docetaxel in metastatic castration-resistant prostate cancer (Phase III)
2012-002814-38Phase 3Completed
- Sponsor
- SOTIO Biotech
- Start
- Apr 2013
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing DCVAC/PCa plus docetaxel and prednisone with Placebo plus docetaxel and prednisone (2 arms). Primary endpoint: Overall Survival. Started Apr 2013; status: completed.
02
Drugs
DCvac
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2012-002814-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002814-38.